West Pharmaceutical Services, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2013. The interim financial statements are unaudited and prepared under U.S. GAAP. The company operates through Pharmaceutical Packaging Systems and Delivery Systems.
Financial performance and condition
| Metric | Q3 2013 | Q3 2012 | 9M 2013 | 9M 2012 |
|---|---|---|---|---|
| Net sales | $341.8 million | $303.8 million | $1,025.7 million | $944.9 million |
| Gross profit | $105.5 million | $90.4 million | $328.1 million | $290.2 million |
| Gross margin | 30.8% | 29.8% | 32.0% | 30.7% |
| Operating profit | $39.7 million | $26.3 million | $125.5 million | $103.6 million |
| Net income | $26.8 million | $14.8 million | $88.7 million | $59.6 million |
| Diluted EPS | $0.37 | $0.21 | $1.25 | $0.85 |
| Operating cash flow | Not provided | Not provided | $151.7 million | $117.6 million |
- Third-quarter sales increased 12.5%, including a $4.9 million favorable foreign-currency effect; constant-currency growth was 10.9%.
- Packaging Systems sales rose 16.5% in the quarter and 9.8% for nine months, driven by higher-value products, packaging components, volume, mix, efficiency, and pricing.
- Delivery Systems sales rose 3.0% in the quarter and 5.5% for nine months. Proprietary products represented 23.6% of segment sales in the quarter versus 21.3% in the prior year.
- Operating margin was approximately 11.6% in Q3 2013 versus 8.7% in Q3 2012. SG&A was 16.4% of sales versus 17.7%.
- Q3 income before taxes was $35.7 million and the effective tax rate was 29.7%; the nine-month rate was 25.9%, compared with 31.7% in the prior-year period.
- At September 30, 2013, cash and cash equivalents were $221.7 million, short-term investments were $7.5 million, and working capital was $396.7 million.
- Total debt was $400.0 million, including $381.1 million of long-term debt. Net debt-to-total invested capital declined to 17.6% from 25.5% at December 31, 2012.
- Capital expenditures were $113.1 million for nine months, primarily related to the new corporate office and research building, an India manufacturing facility, and expansion and product projects.
- Cash flow from operations of $151.7 million exceeded capital expenditures, while investing activities used $111.0 million and financing activities provided $18.4 million. Ending cash increased by $59.8 million from year-end 2012.
Material changes versus prior comparable periods
- Q3 net income increased 81.1%, and operating profit increased 51.0%, primarily from higher sales, improved Packaging Systems margins, production efficiencies, pricing, and lower restructuring-related costs.
- Nine-month net income increased 48.8%, while operating profit increased 21.1%.
- Delivery Systems profitability weakened: segment operating profit was a $0.1 million loss in Q3 versus $4.7 million profit in the prior year, mainly because of lower profitability on pre-clinical CZ cartridge volumes and higher labor, benefit, and raw-material costs.
- 2012 included materially higher unusual costs, including an $11.6 million debt-extinguishment loss, a $3.4 million impairment charge, and restructuring charges. The comparable 2013 debt-extinguishment loss was $0.2 million, and no 2013 restructuring charges were recorded.
- In June 2013, the company received a nonrefundable $20.0 million customer payment for exclusive use of SmartDose in a specified therapeutic area. The payment is being recognized as development income over 13 years; $19.3 million remained unearned at September 30, 2013.
- The company completed a two-for-one stock split in September 2013. Share and per-share data have been retroactively adjusted.
Outlook, risks, contingencies, and unusual items
- Management expects continued revenue improvement from customers adopting higher-value Packaging Systems products, growth in proprietary Delivery Systems products, capacity expansion, lean savings, and emerging-market investments. No specific numerical earnings or revenue guidance was provided.
- Management expects to continue funding capital projects for new products, expansion, and emerging markets.
- Liquidity is expected to be adequate through cash, operating cash flow, and available revolving-credit capacity. The company had $216.6 million of borrowing capacity under its multi-currency revolving facility and was in compliance with debt covenants.
- Key risks include customer demand and ordering patterns, competition and pricing pressure, regulatory approval and commercialization of customer products, product mix, production and supply-chain execution, reliance on third-party suppliers including Daikyo, skilled-labor availability, petroleum-based raw-material costs, foreign-exchange movements, and healthcare legislation.
- SmartDose contingent consideration was $3.8 million at September 30, 2013. Changes depend on sales projections and discount rates and could materially increase or decrease the liability.
- The company uses interest-rate, foreign-exchange, and commodity hedges. Variable-rate debt and foreign-currency operations remain sources of market risk.
- The company reported no material changes to previously disclosed commitments, contingencies, or risk factors; no legal proceedings were reported in Part II, Item 1.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2013, with no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether Packaging Systems growth and margin gains persist and offset weaker Delivery Systems profitability.
- The timing, regulatory progress, customer adoption, and commercial economics of SmartDose, CZ, and other proprietary products.
- The sustainability of operating cash flow after elevated capital expenditures and the effect of the $20.0 million SmartDose payment on reported cash flow.
- Debt maturities, variable-rate exposure, covenant compliance, and available revolving-credit capacity.
- Potential changes in SmartDose contingent consideration based on revised sales projections and discount rates.
- Exposure to foreign exchange, petroleum-based raw-material costs, supply-chain constraints, customer concentration, and regulatory or healthcare-policy changes.